Načítá se...
Is there still a place for docetaxel rechallenge in prostate cancer?
Three-weekly docetaxel plus prednisone is the standard first-line cytotoxic treatment for patients with metastatic castrate-resistant prostate cancer (mCRPC). Today, several new treatment options are available for patients with tumor progression after first-line docetaxel: Abiraterone, enzalutamide,...
Uloženo v:
| Vydáno v: | World J Clin Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4600198/ https://ncbi.nlm.nih.gov/pubmed/26468445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5306/wjco.v6.i5.99 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|